Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers
A Tursi, W Elisei, R Faggiani, L Allegretta… - Medicine, 2018 - journals.lww.com
Adalimumab (ADA) was approved in Italy for the treatment of ulcerative colitis (UC)
unresponsive to standard treatments in 2014, but no data from real life are currently
available. The aim of the present study was to assess the real-life efficacy and safety of ADA
in managing UC outpatients in some Italian primary inflammatory bowel disease (IBD)
centers after approval of ADA reimbursement.
unresponsive to standard treatments in 2014, but no data from real life are currently
available. The aim of the present study was to assess the real-life efficacy and safety of ADA
in managing UC outpatients in some Italian primary inflammatory bowel disease (IBD)
centers after approval of ADA reimbursement.
以上显示的是最相近的搜索结果。 查看全部搜索结果